We are planning a first in man clinical trial with our soft topical MEK inhibitor in 2019. This trial will evaluate multiple doses levels and a matching placebo in patients with cutaneous neurofibromas and epidermal nevi. Further details will be available shortly.

Current Investors

Address: NFlection Therapeutics, Inc., One Broadway, 14th Floor, Cambridge, MA 02142

Email: info@nflectionrx.com

logo 4png.png